PTGX
Protagonist Therapeutics Inc
$20.73
Earnings Summary
Revenue | $0Mn |
Net Profits | $-31.23Mn |
Net Profit Margins | -Inf% |
Highlights
Protagonist Therapeutics Inc’s revenue fell -100% since last year same period to $0Mn in the Q3 2022. On a quarterly growth basis, Protagonist Therapeutics Inc has generated -100% fall in its revenue since last 3-months.
Protagonist Therapeutics Inc’s net profit jumped 7.61% since last year same period to $-31.23Mn in the Q3 2022. On a quarterly growth basis, Protagonist Therapeutics Inc has generated 23.89% jump in its net profits since last 3-months.
Protagonist Therapeutics Inc’s net profit margin fell -Inf% since last year same period to -Inf% in the Q3 2022. On a quarterly growth basis, Protagonist Therapeutics Inc has generated -Inf% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Protagonist Therapeutics Inc post its latest quarter earnings
EPS Estimate Current Quarter | -0.64 |
EPS Estimate Current Year | -0.64 |
Highlights
Protagonist Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.64 - a 26.44% jump from last quarter’s estimates.
Protagonist Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.64.
Key Ratios
Key ratios of the Protagonist Therapeutics Inc post its Q4 2022 earnings
Return on Assets (ROA) | -0.28 |
Return on Equity (ROE) | -0.49 |
Highlights
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Protagonist Therapeutics Inc’s return on assets (ROA) stands at -0.28.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Protagonist Therapeutics Inc’s return on equity (ROE) stands at -0.49.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2018-03-07 | -0.35 | -0.15 | 57.14% |
2017-05-10 | -0.61 | -0.84 | -37.7% |
2017-08-08 | -0.86 | -0.89 | -3.49% |
2017-11-07 | -0.71 | -0.29 | 59.15% |
Company Information
Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. Rusfertide (PTG-300) is an injectable hepcidin mimetic in a Phase 2 proof-of-concept clinical trial for polycythemia vera, and a separate Phase 2 clinical study for hereditary hemochromatosis. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in a 150 patient Phase 2 study for the potential treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease. Two additional second-generation oral interleukin-23 receptor antagonist candidates PN-235 and PN-232, are in early stages of clinical development. The Company has developed a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms.
Organisation | Protagonist Therapeutics Inc |
Headquarters | 7707 Gateway Boulevard, Newark, CA, United States, 94560-1160 |
Employees | 105 |
Industry | Health Technology |
